| Previous Close | 57.02 |
| Open | 56.94 |
| Bid | 56.25 x 100 |
| Ask | 59.48 x 200 |
| Day's Range | 55.51 - 57.36 |
| 52 Week Range | 33.97 - 58.11 |
| Volume | 502,169 |
| Avg. Volume | 245,948 |
| Net Assets | 342.04M |
| NAV | 45.61 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 14.18% |
| Beta (3y) | 3.05 |
| Expense Ratio (net) | 0.95% |
| Inception Date | 2010-04-06 |
- Investopedia•5 months ago
Trump Foreshadows a Bleak Outlook for Biotech
Biotech sector stocks surged after the election, but pulled back when Trump targeted drug companies.
- Market Realist•6 months ago
What Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
- Market Realist•6 months ago
Horizon Pharma’s Steep Fall in December: What Happened?
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn't meet its primary endpoint. Horizon stock fell 22.5% that day.